StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $36.57 | $35.23 | -3.66% | 0.5M |
| 05-12 | $35.23 | $35.97 | +2.10% | 0.3M |
| 05-13 | $35.40 | $35.55 | +0.42% | 0.3M |
| 05-14 | $35.73 | $36.34 | +1.71% | 0.4M |
| 05-15 | $36.23 | $35.49 | -2.04% | 0.4M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
No sell-side coverage available for CNMD.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for CNMD.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Each factor shows CNMD's percentile within the scored universe — observational ranking, not a recommendation.
| Metric | Q3 2026 (Est.) Expected 2026-07-28 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|---|
Revenue | $344.24M | $1.37B | $1.00B | $663.60M | $321.26M |
Operating Income | Not available | $102.62M | $66.00M | $54.12M | $15.96M |
Net Income | Not available | $47.05M | $30.32M | $27.46M | $6.04M |
EPS (Diluted) | $1.13 | $1.51 | $0.97 | $0.88 | $0.19 |
Total Assets | Not available | $2.33B | $2.32B | $2.33B | $2.30B |
Total Liabilities | Not available | $1.29B | $1.31B | $1.33B | $1.32B |
Cash & Equivalents | Not available | $40.82M | $38.93M | $33.94M | $35.48M |
Free Cash Flow OCF − CapEx | Not available | $150.88M | $109.66M | $61.16M | $37.76M |
Shares Outstanding | Not available | 31.15M | 31.14M | 31.14M | 31.15M |
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
CNMD is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1138-name primary list.
DNA analysis is not available for this ticker.